After 2 Drug Approvals, Can Supernus Deliver In 2013?

Healthcare Sector and Stocks Analysis from Seeking Alpha

Mon, 26 Nov 2012

By C.R. Jackson : Supernus Pharmaceuticals ( SUPN ) is developing a central nervous system ( CNS ) portfolio with proprietary extended release technologies. While most shareholders are investing in Supernus because of the strength of the company's epilepsy and attention deficit-hyperactivity ...

Read the rest of this article on Healthcare Sector and Stocks Analysis from Seeking Alpha

Related Topics:

Related Videos

First Day Pop Doesn't Spell Long-Term Success for IPOs

Tue, 15 May 2012

Recent tech IPOs have had great first days, but performance has lagged since then, says Morningstar's James Krapfel.

Content Partners

Site Directory Site Map Our Products

Corrections Help Advertising Opportunities Licensing Opportunities Glossary RSS Mobile Portfolio Affiliate Careers Company News

International Sites: Australia Canada China France Germany Hong Kong Italy The Netherlands Norway Spain U.K. Switzerland India Finland

Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.

© Copyright 2013 Morningstar, Inc. All rights reserved. Please read our Terms of Useand Privacy Policy.Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.